LifeMD (LFMD) Net Income towards Common Stockholders (2012 - 2025)

LifeMD has reported Net Income towards Common Stockholders for 14 years, with the latest figure at $19.2 million in Q4 2025.

• For the quarter ending Q4 2025, Net Income towards Common Stockholders rose 356.46% year-over-year to $19.2 million; the trailing twelve-month figure through Mar 2026 stood at $15.1 million (up 169.95% YoY), and the FY2025 full-year result was $11.2 million, up 142.8% from the prior year.
• Net Income towards Common Stockholders for Q4 2025 stood at $19.2 million, up from -$4.6 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $19.2 million in Q4 2025, with the low at -$19.0 million in Q4 2021.
• Historically, Net Income towards Common Stockholders has averaged -$7.4 million across 5 years, with a median of -$7.5 million in 2023.
• Annual changes were most pronounced in 2021 — Net Income towards Common Stockholders sank 398.08% — and 2025, when it jumped 356.46%.
• LifeMD's Net Income towards Common Stockholders stood at -$19.0 million in 2021, then surged by 33.03% to -$12.7 million in 2022, then jumped by 64.53% to -$4.5 million in 2023, then tumbled by 65.94% to -$7.5 million in 2024, then soared by 356.46% to $19.2 million in 2025.
• The last three Net Income towards Common Stockholders figures came in at $19.2 million (Q4 2025), -$4.6 million (Q3 2025), and $455210.0 (Q2 2025), per Business Quant data.